New Treatment for Advanced Prostate Cancer

	Tweet

Researchers at the University of Adelaide have developed a novel approach to treating advanced prostate cancer that could be more effective with fewer side effects.

Professor Wayne Tilley and Dr Lisa Butler of the University’s Dame Roma Mitchell Cancer Research Laboratories have discovered that by using existing prostate cancer drugs in combination with new drugs at lower doses, they can expect to generate better results for patients than current treatments.

Growth of prostate cancer is initially dependent on hormones called androgens, which traditionally have been suppressed to stop tumour growth. However, despite an initial response, resistance to hormone deprivation often occurs and the tumour starts to grow again, Professor Tilley says.

“Men undergoing hormone deprivation therapy can also experience significant side effects, including reduced libido, impotence, hot flushes, tiredness and sweating, gradual decrease in body hair, reduced bone and muscle strength and cognitive changes,” he adds.

Professor Tilley and Dr Butler have successfully killed prostate cancer cells in laboratory studies using low doses of a combination therapy of drugs including bicalutamide (an anti-androgen that opposes the action of androgen on the tumour), and the inhibitors 17AAG and vorinostat.

These new drugs block key cancer survival pathways, but are not particularly effective in killing prostate cancer cells if given alone.

“We can now confirm that a very low level of bicalutamide is capable of inhibiting cancer cell proliferation by more than 10-fold when combined with either vorinostat or 17AAG, making our current treatments much more effective and causing fewer side effects,” says Dr Lisa Butler.

All the drugs needed for combination therapy are already approved for use in clinical trials, so the new therapy can be readily tested in patients with advanced prostate cancer.

Professor Chris Sweeney, a world recognised medical oncologist and Director of Clinical Trials at the Royal Adelaide Hospital Cancer Centre, will lead a multidisciplinary team to test the new treatment.

“The ultimate test of this exciting laboratory breakthrough is to see if it improves outcomes and quality of life for men suffering from advanced prostate cancer,” he says.

“The strong partnership between medical scientists and clinicians at the University of Adelaide and the Royal Adelaide Hospital means patients can benefit from advances in medical science much faster than in the past.”

Professor Tilley is a founding member of the Freemasons Foundation Centre for Men’s Health, which is working towards establishing a national prostate cancer research facility in Adelaide.

Source: University of Adelaide

RELATED STORIES:
Clinicians Map Group at High Risk for Aggressive, ‘Hidden’ Prostate Cancer   Men, Don’t Skip Your Prostate Cancer Treatment Appointments!   Radiation therapy technique reduces length of prostate cancer treatment   Herbal extract may treat prostate cancer   New data show benefit of finasteride in preventing prostate cancer   Smoking Associated with Worse Outcomes in Patients with Prostate Cancer Treated by Radical Radiother   Novel drug selectively kills prostate cancer cells   Combination therapy improves survival for certain prostate cancer patients   Waiting on prostate treatment not distressing for most   Drug Attacks Prostate Cancer in Mouse Model by Destroying Its Blood Supply   New Web site Helps Doctors and Prostate Cancer Patients Make Better Treatment Choices   Prostate technique provides new insights   MRI findings help forecast prostate cancer prognosis   Gene test could save men from prostate surgery   Prostate Cancer Translational Research in Europe meeting: Search for biomarkers continues   Brisk walking may help men with prostate cancer, UCSF study finds   Link Uncovered Between Benign Prostatic Hyperplasia, NSAIDs   Early prostate cancer detection, screening: No benefit for men with low baseline PSA value   Height linked to risk of prostate cancer development and progression   How Advanced Prostate Cancer Becomes Resistant to Androgen-deprivation Therapy   Generic Prostate Drug Helps Find High-risk Cancers Early   Gene Markers Located for Hereditary Prostate Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]